B-cell Counts and Inflammation Markers Predicting Prevalence and Severity of Cytokine-Release Syndrome in CAR T-Cell Therapy of Patients with Autoimmune Disease (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2940; Pres time: Nov 11, 2026; 10:45 AM - 11:00 AM; Location: W415BC; In Person; "Patients from Germany were either treated with autologous CD19 CAR-T in a named patient use program, in the phase 1/2 CASTLE trial, or in a phase 1 trial with BMS-986353...Patients received lymphodepletion (LD) with cyclophosphamide and fludarabine prior to CAR-treatment... Pre-treatment B-cell burden and inflammatory state correlate with risk of CRS occurrence. Simple B-cell counts and interleukin-6 can serve as CRS-prediction biomarkers. Strategies for B-cell depletion and systemic inflammation suppression prior to CAR T therapy could lead to a safer therapy approach.References:1."
CAR T-Cell Therapy • Clinical • Cytokine release syndrome • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Immunology • Inflammation • Inflammatory Arthritis • Leukemia • Lupus • Myositis • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • CRP • IL6
|
|
Shirley Chan1; Koray Tascilar2; Andreas Wirsching2; Soraya Kharboutli3; Fabian Mueller3; He Huang4; Jingjing Feng4; HUJI XU5; Ann-Christin Pecher6; Joerg Henes7; Ioanna Minopoulou8; David Simon9; Gerhard Krönke10; Denise Walther11; Dimitrios Mougiakakos11; Christina Duesing12; Joerg Distler13; Isabell Haase14; Martin Krusche15; Tobias Krickau16; Markus Metzler16; Laura Bucci2; Simon Voelkl3; Tobias Rothe17; Jule Bachl18; Andreas Mackensen19; Ricardo Grieshaber-Bouyer20; Georg Schett21; Melanie Hagen2
|